Eli Lilly has signed another bolt-on deal to bulk up its pipeline, this time paying $47.5 million upfront for rights to a non-opioid analgesic drug developed by US biotech Centrexion Therapeutics.

4528.T Ono Pharmaceutical Co., Ltd.

As of February 21 at 3:00:00 PM EST. Market Open.